AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22429273
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive administered 30 minutes after exenatide
Trial: 22429273
Drug: Repeated daily
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated daily oral contraceptive administration 30 minutes after exenatide
Trial: 22429273
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive administered 1 hour before exenatide
Trial: 21246844
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (Shenmen (HT 7), Baihui (CV 20), Hegu (LI 4), Taichong (LR 3))
Trial: 21246844
Drug: Trazodone (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (oral administration for 4 weeks)
Trial: 14598513
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of naltrexone and SSRI antidepressants
Trial: 8309864
Drug: HMG-CoA reductase
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG-CoA reductase inhibitors and gemfibrozil (Lopid)
Trial: 2453766
Drug: Birth control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth control vaccine (synthetic peptide antigen representing the aminoacid sequence 109‐145 of the C‐terminal region of the beta subunit of human chorionic gonadotropin)
Trial: 22782995
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 10 ml/kg
Trial: 22782995
Drug: Dopamine 2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine 2.5-5 mcg/kg per min
Trial: 16904519
Drug: AF+C (Accelerated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AF+C (Accelerated Fractionation with Concurrent Chemotherapy)
Trial: 16904519
Drug: CF+C (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CF+C (Conventional Fractionation with Concurrent Chemotherapy)
Trial: 16904519
Drug: Both CRT
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both CRT arms (Concurrent Chemoradiotherapy)
Trial: 8873700
Drug: Bromocriptine mesylate
RxNorm normalized name: Bromocriptine Mesylate
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bromocriptine mesylate (12.5 mg/day for 28 days)
Trial: 1676367
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fenoldopam and enalapril
Trial: 26426577
Drug: ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.1% and clonidine 1.5 μg ml⁻¹ (RC1.5 group; n = 65)
Trial: 26426577
Drug: ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.1% and clonidine 3 μg ml⁻¹ (RC3 group; n = 65)
Trial: 26426577
Drug: ropivacaine 0.1%
RxNorm normalized name: ROPivacaine 0.1% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ropivacaine 0.1% and sufentanil 0.25 μg ml⁻¹ (RS group; n = 65)
Trial: 26426577
Drug: Clonidine 3 μg ml⁻¹
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 3 μg ml⁻¹
Trial: 22944391
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg/2 mL)
Trial: 22944391
Drug: Pheniramine hydrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pheniramine hydrogen maleate (45.5 mg/2 mL)
Trial: 19586514
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LHR treatment)
Trial: 19586514
Drug: Side effects
RxNorm normalized name: cured fat, pork side bacon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Side effects of LHR treatment
Trial: 15344695
Drug: Budesonide, 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, 4 mg/day
Trial: 15344695
Drug: Intravenous prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous prednisolone, 120 mg/day
Trial: 15344695
Drug: Oral prednisolone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone, 30 mg/day
Trial: 7677241
Drug: Sedating antihistamines
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedating antihistamines (triprolidine, diphenhydramine, clemastine)
Trial: 7677241
Drug: Nonsedating antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsedating antihistamines (terfenadine, loratadine, cetirizine, acrivastine, mizolastine, ebastine)
Trial: 2509528
Drug: recombinant tissue-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant tissue-type plasminogen activator (rt-PA) administration
Trial: 25400062
Drug: Prasugrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel plus aspirin for 30 months
Trial: 23873976
Drug: High-dose nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nicotine patch therapy (42mg/day)
Trial: 11104593
Drug: EPA-EE (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA-EE (6 g/d)
Trial: 11104593
Drug: Placebo (OA-EE;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (OA-EE; 6 g/d)
Trial: 28987023
Drug: Soluble hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble hyaluronic acid (HA) microneedle patch plus adenosine wrinkle cream
Trial: 28987023
Drug: Soluble hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Soluble hyaluronic acid (HA) microneedle patch alone
Trial: 28987023
Drug: Adenosine wrinkle
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adenosine wrinkle cream alone
Trial: 22397651
Drug: Donepezil and
RxNorm normalized name: donepezil and memantine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil and memantine combination
Trial: 20142596
Drug: Individualized prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized prescribed total tumor dose (TTD) based on normal tissue dose constraints (mean lung dose, 19 Gy; maximal spinal cord dose, 54 Gy) up to a maximal TTD of 79.2 Gy in 1.8 Gy fractions twice daily
Trial: 15821265
Drug: Antiviral drug
RxNorm normalized name: antiviral drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral drug prophylaxis
Trial: 12349850
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance treatment with new drugs
Trial: 10368053
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene (OH)
Trial: 8665547
Drug: Pramipexole (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (4.5 mg/day maximum)
Trial: 2183619
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (Methyldopa, Labetalol, No medication)
Trial: 30111233
Drug: Electronic Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic Tablet (ET) classes
Trial: 19915221
Drug: Cangrelor (intravenous,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cangrelor (intravenous, administered 30 minutes before PCI and continued for 2 hours after PCI)
Trial: 19915221
Drug: Clopidogrel (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (600 mg oral loading dose, administered 30 minutes before PCI)
Trial: 9701531
Drug: Rabeprazole 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 30 mg
Trial: 2553528
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (1500 aPTT once daily)
Trial: 2553528
Drug: Sodium heparin
RxNorm normalized name: Heparin Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium heparin (5000 IU three times daily)
Trial: 31104832
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of fIPV (Group D)
Trial: 28899892
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioural therapy (ICBT) for 15 weeks
Trial: 28899892
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural group therapy (CBGT) for 15 weeks
Trial: 26658938
Drug: Community Treatment
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Treatment Assistants (CTAs) with additional half-day training and a TT screening card
Trial: 12535752
Drug: L-thyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine treatment in patients with subclinical hypothyroidism (SCH)
Trial: 10908004
Drug: Eight models
RxNorm normalized name: OC Eight
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eight models of outpatient treatment for methamphetamine dependence (treatment-as-usual)
Trial: 1538597
Drug: No-touch technique
RxNorm normalized name: Lysol No-Touch Hand Soap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-touch technique without any other preparation aids (Group I)
Trial: 1538597
Drug: Distention at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distention at 70-120 mm Hg with balanced pH electrolyte solution (Group II)
Trial: 1538597
Drug: Distention at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distention at 70-120 mm Hg with balanced pH electrolyte solution plus nitroglycerin (1 microgram/ml) (Group III)
Trial: 6377994
Drug: Intermittent Positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Positive Pressure Breathing (IPPB) for 15 min 4 times daily
Trial: 6377994
Drug: Incentive Spirometry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incentive Spirometry (IS) 4 times daily
Trial: 6377994
Drug: Deep Breathing
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Breathing Exercises (DBE) for 15 min 4 times daily
Trial: 6377994
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no respiratory treatment)
Trial: 24901305
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g carbohydrate (sucrose) 45 min before exercise
Trial: 24901305
Drug: 2 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 × 0.2 g · kg‐1 sodium bicarbonate (NaHCO3) 90 and 20 min before exercise
Trial: 24901305
Drug: Placebo (H2O
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (H2O for carbohydrate group, 2 × 0.14 g · kg‐1 NaCl for sodium bicarbonate group)
Trial: 20214718
Drug: LC 40
RxNorm normalized name: talc 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC 40 mg
Trial: 20214718
Drug: LC 80
RxNorm normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LC 80 mg
Trial: 18797094
Drug: Soft occlusal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft occlusal splint therapy
Trial: 18797094
Drug: Pharmacotherapy (muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy (muscle relaxants and analgesics)
Trial: 29092729
Drug: Zaltoprofen capsule
DrugBank: Zaltoprofen (DB06737)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Zaltoprofen capsule (80 mg) under fasting state
Trial: 29092729
Drug: Zaltoprofen tablet
DrugBank: Zaltoprofen (DB06737)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Zaltoprofen tablet (80 mg) under fasting state
Trial: 29092729
Drug: Zaltoprofen capsule
DrugBank: Zaltoprofen (DB06737)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Zaltoprofen capsule (80 mg) under fed state
Trial: 29092729
Drug: Zaltoprofen tablet
DrugBank: Zaltoprofen (DB06737)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Zaltoprofen tablet (80 mg) under fed state
Trial: 10702455
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg (Group T20)
Trial: 10702455
Drug: Tenoxicam 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 40 mg (Group T40)
Trial: 10702455
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 4 mL (Group NS)
Trial: 8174947
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg twice daily) + Cisapride (20 mg twice daily)
Trial: 3985039
Drug: Prednisone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (30 mg daily)
Trial: 3985039
Drug: Aerosol beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol beclomethasone (16 puffs daily)
Trial: 15620828
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of piperacillin-tazobactam
Trial: 6374680
Drug: Piretanide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piretanide (2 x 6 mg daily)
Trial: 6374680
Drug: Hydrochlorothiazide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (2 x 25 mg daily)
Trial: 6374680
Drug: Hydrochlorothiazide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (2 x 50 mg daily)
Trial: 30022544
Drug: BF-200 ALA
RxNorm normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF-200 ALA gel (7.8% 5-aminolaevulinic acid)
Trial: 30022544
Drug: MAL cream
RxNorm normalized name: PLO Transdermal Cream
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL cream (16% methyl-aminolaevulinate)
Trial: 30022544
Drug: BF-200 ALA
RxNorm normalized name: ALA
DrugBank: alpha-Linolenic acid (DB00132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BF-200 ALA gel
Trial: 17428114
Drug: Rosiglitazone (2,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (2, 4, or 8 mg tablets once daily)
Trial: 11860415
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg b.d.), Clarithromycin (500 mg b.d.), Amoxicillin (1 g b.d.)
Trial: 11860415
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.d.), Bismuth subsalicylate (600 mg q.d.s.), Metronidazole (400 mg t.d.s.), Tetracycline (500 mg q.d.s.)
Trial: 7615102
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (GnRH‐a) - 1,000 micrograms intranasal buserelin acetate daily for 4 weeks, followed by hMG in weekly augmented doses (2, 4, and 6 ampules daily for 3 weeks)
Trial: 7615102
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - no active treatment for 4 weeks, followed by hMG in weekly augmented doses (2, 4, and 6 ampules daily for 3 weeks)
Trial: 2798990
Drug: Phenformin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenformin (50 mg bid)
Trial: 299896
Drug: Aspirin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (4 gm/day)
Trial: 299896
Drug: Acetaminophen (14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (14 days prior to each period)
Trial: 30592553
Drug: Paxerol (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paxerol (325 mg acetaminophen and 150 mg ibuprofen per tablet) at low dose (1 tablet), mid dose (2 tablets), and high dose (3 tablets) for 14 days
Trial: 30592553
Drug: Paxerol (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paxerol (high dose)
Trial: 25495209
Drug: Community Treatment
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Treatment Orders (CTO)
Trial: 23619906
Drug: Magnesium supplementation
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium supplementation (250 mg magnesium oxide daily for 8 weeks)
Trial: 16924991
Drug: Bleaching +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching + 10% sodium ascorbate solution
Trial: 16924991
Drug: Bleaching (10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleaching (10% carbamide peroxide gel)
Trial: 15020394
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy by a research GP near their home address
Trial: 16808802
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine patches (25 mg/day)
Trial: 10561343
Drug: Concurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent therapy (cisplatin 80 mg/m² on days 1 and 29, vindesine 3 mg/m² on days 1, 8, 29, and 36, mitomycin 8 mg/m² on days 1 and 29, RT starting on day 2 at 28 Gy)
Trial: 10561343
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (same chemotherapy but RT initiated after completing CT at 56 Gy)
Trial: 1789063
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms iodide/day (initial treatment) followed by 100 micrograms levothyroxine and 100 micrograms iodide/day (combination treatment)
Trial: 7011035
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics (2 million IU of penicillin G intramuscularly before and after the procedure, followed by 350 mg of pivampicillin three times daily for 4 days)
Trial: 30177038
Drug: rhAPC (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhAPC (24 μg/kg/hr for ≤96 h antenatally)
Trial: 2231833
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg flumazenil (group 1)
Trial: 2231833
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg flumazenil (group 2)
Trial: 2231833
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg flumazenil (group 3)
Trial: 2231833
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg flumazenil (group 4)
Trial: 2231833
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg flumazenil
Trial: 26786311
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (folic acid 2.5 mg/day, vitamin B6 50 mg/day, vitamin B12 1 mg/day)
Trial: 24163081
Drug: Localized P2
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Localized P2 receptor blockade (pyridoxal‐5‐phosphate)
Trial: 19596954
Drug: Lentinan plus
RxNorm normalized name: lentinan
DrugBank: Lentinan (DB13480)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentinan plus chemotherapy
Trial: 15086284
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of enoxaparin administered subcutaneously once daily for 10 (+/‐4) days
Trial: 15086284
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of enoxaparin administered subcutaneously once daily for 10 (+/‐4) days
Trial: 15086284
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered subcutaneously once daily for 10 (+/‐4) days
Trial: 12204931
Drug: Psychological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological treatment (graded exercise)
Trial: 2698591
Drug: Induction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of labor by stripping of membranes and i.v. oxytocin infusion, with artificial rupture of membranes when the cervical opening was 3 cm or more in diameter.
Trial: 338079
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (10 g during the first 2 1/2 days)
Trial: 27745812
Drug: bivalent rLP2086
RxNorm normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bivalent rLP2086 (120 μg)
Trial: 22801243
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G-GR) 1800 mg
Trial: 16053850
Drug: Clonidine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (15 microg/ml)
Trial: 16053850
Drug: Epinephrine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (12.5 microg/ml)
Trial: 10065788
Drug: MH61 monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MH61 monoclonal antibody
Trial: 10065788
Drug: Two-color fluorescence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-color fluorescence staining with FITC-PSA and anti-CD46 monoclonal antibody
Trial: 2207824
Drug: Propofol (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.2 mg/kg)